# Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV

> **NCT06624839** · PHASE2 · RECRUITING · sponsor: **University of Maryland, Baltimore** · enrollment: 120 (estimated)

## Conditions studied

- Human Papilloma Virus
- Anal Dysplasia
- HIV

## Interventions

- **BIOLOGICAL:** Human papillomavirus (HPV) vaccine, 9-valent

## Key facts

- **NCT ID:** NCT06624839
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-15
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06624839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06624839, "Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT06624839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*